Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Lauper

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Annals of the Rheumatic Diseases|December 31, 2024
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Kim Lauper, Juan Molina-Collada, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Annals of the Rheumatic Diseases|December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases|February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Journal of Internal Medicine|May 13, 2022
One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individualsMayssam Nehme, Olivia Braillard, François Chappuis, et al.
Preventive Medicine Reports|July 13, 2022
The pandemic toll and post-acute sequelae of SARS-CoV-2 in healthcare workers at a Swiss University HospitalMayssam Nehme, Laure Vieux, Delphine S Courvoisier, et al.
Autoimmunity Reviews|December 16, 2020
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' ConsensusRoberto Giacomelli, Antonella Afeltra, Elena Bartoloni, et al.
Annals of the Rheumatic Diseases|November 10, 2022
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateJosef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Annals of the Rheumatic Diseases|December 31, 2024
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Kim Lauper, Juan Molina-Collada, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Annals of the Rheumatic Diseases|December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases|February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Journal of Internal Medicine|May 13, 2022
One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individualsMayssam Nehme, Olivia Braillard, François Chappuis, et al.
Preventive Medicine Reports|July 13, 2022
The pandemic toll and post-acute sequelae of SARS-CoV-2 in healthcare workers at a Swiss University HospitalMayssam Nehme, Laure Vieux, Delphine S Courvoisier, et al.
Autoimmunity Reviews|December 16, 2020
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' ConsensusRoberto Giacomelli, Antonella Afeltra, Elena Bartoloni, et al.
Annals of the Rheumatic Diseases|November 10, 2022
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateJosef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, et al.
Pageof 7